Skip to main content
. 2015 May 8;2(7):699–705. doi: 10.1016/j.ebiom.2015.05.003

Table 2.

Characteristics of recipients stratified for quartile of CMV doubling time.

Characteristics
1st quartile
2nd quartile
3rd quartile
4th quartile
p-Value
N = 49 N = 48 N = 48 N = 48
Median CMV doubling time (IQR), days 1.7 (1.4–2.1) 3.4 (2.9–3.9) 5.6 (4.7–6.6) 12.0 (9.2–21.2)
Median age, years (IQR) 51 (34–62) 47.5 (33–58) 47 (24–57) 45 (36–54.5) 0.7
Gender (proportion of males) 36/49 (73%) 31/48 (65%) 34/48 (71%) 32/48 (67%) 0.3
Median proportion of time during CMV infection on treatment (IQR) 0.33 (0–0.75) 0.43 (0–0.81) 0.62 (0.21-0.85) 0.61 (0–0.85) 0.3
Type of transplantation
 Proportion of SOT recipients 22/49 (45%) 15/48 (31%) 15/48 (31%) 22/48 (46%) 0.2
 Proportion of HSCT recipients 27/49 (55%) 33/48 (69%) 33/48 (69%) 26/48 (54%) 0.2
Risk of CMV infection
 Proportion at high risk 28/49 (57%) 20/48 (42%) 28/48 (58%) 20/48 (42%) 0.2
 Proportion at intermediary/low risk 21/49 (43%) 28/48 (58%) 20/48 (42%) 28/48 (58%) 0.2
Median V1 (IQR) IU/mL 1001 (455–3640) 1147 (546–3076) 915 (455–4596) 1911 (814–14,560) 0.02
Median Vpeak (IQR) IU/mL 18,200 (4186–58,240) 5779 (1957–17,290) 3044 (1456–12,376) 3504 (1124–31,987) 0.01
Proportion of recipients with symptomatic CMV infection1 22/48 (46%) 9/46 (20%) 14/47 (30%) 14/47 (30%) 0.01⁎⁎
Proportion of recipients with allograft rejection or GVHD 7/49 (14%) 9/48 (19%) 10/48 (21%) 10/48 (21%) 0.4
1

For five HSCT recipients, data regarding CMV disease was unavailable.

The median V1 was not significantly different when comparing the 1st, 2nd and 3rd quartiles. The 4th quartile had a significantly higher V1 sample compared to the 1st quartile, p = 0.02.

⁎⁎

There was a significantly higher proportion of symptomatic CMV infection when comparing the 1st quartile to the 2nd, however this was not persistent when comparing the 1st quartile to the two other quartiles (p > 0.1).